| Patient | Georgia O'Keeffe |
|---|---|
| Date of birth | 1945-11-15 |
| Identifiers | MRN HR-ET011-SYN; SSN (made up) 000-11-5873 |
| Document date | 2026-07-02 |
| Author | Wendell Ashby, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Treat-and-extend retina visit and primary care review of vision rehabilitation. [S]
Ms. O'Keeffe returns eight weeks after her third injection, the first extended interval. Her left-eye vision has held, with no new distortion, and daily Amsler checks of each eye show no change. Low-vision rehabilitation is complete: task lighting and a stand magnifier are set up in the studio, and high-contrast labels mark her paints and household controls. She is painting daily. The driving assessment cleared her for short local routes by day. She takes the AREDS2 supplement daily and has had no falls. [S]
| Element | Detail |
|---|---|
| Interval change | Left-eye vision stable over eight weeks; no new distortion |
| Amsler grid | Daily checks of each eye; no change |
| Low-vision rehabilitation | Task lighting, stand magnifier, and high-contrast labels in place |
| Driving | Cleared for short local routes by day |
| Function | Painting daily; independent at home; no falls |
| System | Result | Finding |
|---|---|---|
| Eyes | Negative | No new distortion, blur, pain, flashes, or floaters |
| Constitutional | Negative | Weight stable; good energy |
| Musculoskeletal | Negative | No falls |
| Psychiatric | Negative | Mood good; PHQ-2 score 0 |
4 systems reviewed. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-07-02 | Body height | 165 | cm | S |
| 2026-07-02 | Body weight | 56.5 | kg | S |
| 2026-07-02 | Body mass index (BMI) [Ratio] | 20.8 | kg/m2 | S |
| 2026-07-02 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-07-02 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-07-02 | Heart rate | 70 | /min | S |
| 2026-07-02 | Respiratory rate | 14 | /min | S |
| 2026-07-02 | Body temperature | 36.7 | Cel | S |
| 2026-07-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-07-02 | Visual acuity best corrected Right eye by ETDRS eye chart | 77 | {letters} | >=80 | Low | S |
| 2026-07-02 | Visual acuity best corrected Left eye by ETDRS eye chart | 70 | {letters} | >=80 | Low | S |
| 2026-07-02 | Macular grid.center subfield thickness by OCT | 268 | um | 200-300 um | Normal | S |
| 2026-07-02 | Right eye Intraocular pressure | 15 | mm[Hg] | 10-21 mmHg | Normal | S |
| 2026-07-02 | Left eye Intraocular pressure | 15 | mm[Hg] | 10-21 mmHg | Normal | S |
| 2026-07-02 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S |
Vital signs recorded on 2026-07-02; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well, energetic |
| Visual acuity | Best-corrected 77 letters right and 70 letters left |
| Intraocular pressure | 15 mmHg in each eye before injection |
| Anterior segment | Quiet in both eyes |
| Dilated fundus, left eye | No fluid or hemorrhage |
| Dilated fundus, right eye | Large drusen unchanged; no fluid or hemorrhage |
| OCT, both eyes | Left eye dry, central subfield thickness 268 µm. Right eye large drusen without fluid |
| After injection, left eye | Optic nerve head perfused; counts fingers; no pain |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Neovascular (wet) age-related macular degeneration, left eye, with active choroidal neovascularization | active | confirmed | H35.3221 | S — Synthetic modern diagnosis linked to her documented failing eyesight; the historical type of macular degeneration is not recorded. |
| Nonexudative age-related macular degeneration, right eye, intermediate stage | active | confirmed | H35.3112 | S — Synthetic finding in the fellow eye. |
| New distortion (wavy lines) and a blurred central spot with reduced acuity in the left eye; suspected neovascular macular degeneration, urgent retina referral | resolved | confirmed | H53.15 | S — Synthetic presenting concern at the index visit, superseded by the OCT diagnosis at the retina consultation; her failing eyesight is documented (D). |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Best-corrected visual acuity (ETDRS letters) | Every injection visit | Completed today | 77 letters right and 70 letters left |
| Imaging | Optical coherence tomography of the macula | Every injection visit | Completed today | Both eyes. Left dry at 268 µm; right drusen without fluid |
| Examination | Intraocular pressure before and after injection | Every injection visit | Completed today | Before injection 15 mmHg in each eye; after injection, optic nerve perfused and counting fingers |
| Examination | Dilated examination of the fellow (right) eye | Every injection visit | Completed today | Large drusen unchanged; no fluid on OCT |
| Examination | Comprehensive dilated eye examination | Every 1 to 2 years at 65 or older | Up to date | Both eyes examined in full at the March retina consultation and again today |
| Medication safety | Intravitreal injection safety | Every injection visit | Completed today | Fourth injection; no complication to date |
| Self-management | Teaching on warning signs of endophthalmitis and retinal detachment | Every injection visit | Completed today | Reviewed again before the ten-week interval |
| Self-management | Daily home Amsler grid, each eye | Daily | Completed today | Daily checks recorded; no change in either eye |
| Medication safety | AREDS2 supplement for intermediate AMD | Daily, long term | Completed today | Taking it daily |
| Referral | Low-vision rehabilitation, with home fall-risk review and a driving assessment | Once central vision is reduced; review as vision changes | Up to date | Completed since the last visit: lighting, magnifier, and labels in place; cleared for short local daytime driving. Review if vision changes |
| Survey | Functional vision assessment (reading, color, driving, work) | At diagnosis; again with change | Completed today | Painting daily with aids; reading with the magnifier; daytime local driving only |
| Survey | Depression screen (PHQ-2) | At follow-up, because vision loss raises the risk of depression; periodically at 65 or older | Completed today | Score 0, down from 1 at intake |
| Survey | Cognitive screen (Mini-Cog) | Annually at 65 or older | Up to date | 5 of 5 at intake in March; next at the annual wellness visit |
Goal progress:
Guideline basis: Age-Related Macular Degeneration Preferred Practice Pattern (2024); CMID: Clinical Monitoring Intelligence Database, cataract and glaucoma monographs (eye-examination items) (2026)
Follow-up: Retina visit in ten weeks for acuity, OCT, pressure, and the fifth injection. Annual wellness visit in the fall. Next scheduled visit 2026-10-15: subsequent annual wellness visit. [S]